UPB
Upstream Bio, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$517.53M
P/E Ratio
—
EPS
$-2.66
Beta
—
52W High
$33.68
52W Low
$7.25
50-Day MA
$8.97
200-Day MA
$18.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $2.85M |
| Gross Profit (TTM) | $2.85M |
| EBITDA | $-160.17M |
| Operating Margin | -6911.00% |
| Return on Equity | -35.40% |
| Return on Assets | -24.00% |
| Revenue/Share (TTM) | $0.05 |
| Book Value | $6.26 |
| Price-to-Book | 1.52 |
| Price-to-Sales (TTM) | 181.34 |
| EV/Revenue | 62.12 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 9.00% |
| Shares Outstanding | $54.42M |
| Float | $34.59M |
| % Insiders | 14.88% |
| % Institutions | 97.36% |
Analyst Ratings
Consensus ($43.57 target)
2
Strong Buy5
Buy1
HoldData last updated: 4/29/2026